Arcus Biosciences, Inc. — Director's Dealing 2018

Mar 19, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2018-03-19

Reporting Person: FALBERG KATHRYN E (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-19	Common Stock	C	17106	—	Acquired	17106	Indirect
2018-03-19	Common Stock	P	30000	$15.00	Acquired	80504	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-19	Series C Convertible Preferred Stock	$	C	17106	Disposed		Common Stock (17106)	Indirect

Footnotes

F1: The total represents shares received upon conversion of shares of Series C Convertible Preferred Stock.

F2: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F3: Represents shares purchased in the Issuer's initial public offering.

F4: The total includes 25,252 shares of Common Stock purchased by the Reporting Person on September 21, 2017 for $2.58 per share pursuant to the exercise of an option granted on September 19, 2017 and an additional 25,252 shares of Common Stock purchased on January 25, 2018 for $5.39 per share pursuant to the exercise of a separate option granted on January 4, 2018.

F5: Represents shares of Series C Convertible Preferred Stock indirectly owned by the Reporting Person as a result of a trust's purchase of such shares from the Issuer on November 6, 2017 for $11.6915 per share.